Investors Back iOmx’s Focus On Tumor Immune Evasion
Developing Anti-Immune Evasion Platform
The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022
The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022